• Company Profile
• Founder's Message
• Company Culture
• Key Milestones
• Company Honor
• Investors

Founder's Message

With unwavering compassion and dedication, Inno Medicine places its trust in the power of science and strives to deliver meaningful benefits to patients.

Over my fifteen-year career as a clinical cardiologist, I have seen many patients afflicted by atherosclerosis who could not receive precise and efficient treatment. Today, while the atherosclerotic population is getting larger and younger, the pace of therapeutic advancements remains disappointingly slow. It was in this context that my team and I embarked on the journey of developing the world's first targeted drug for atherosclerosis.

Conceived from a research grant in 2015, Inno Medicine was founded in 2016. Over the course of the following seven years, the idea evolved into a clinical investigational product in 2022. This journey was both challenging and rewarding, during which Inno Medicine lived up to the expectations of medical experts, the trust of shareholders, and the hard work of the team by successfully translating the R&D idea and experiment data into commercial manufacturing capabilities. As a matter of fact, we began with nothing but a rented public platform for molecule discovery. Milestones were achieved as we progressed: in 2018, the establishment of our own lab; in 2019, inauguration of our pilot plant; and in 2023, a full-fledged commercial manufacturing site being commissioned. With unwavering compassion and dedication, Inno Medicine places its trust in the power of science and strives to deliver meaningful benefits to patients.

Our persistent efforts have yielded gratifying results. The targeted drug delivery platform we developed garnered recognition from US FDA and China NMPA for its breakthroughs, which is a good first step for the NDA submission in China and the US so that the novel drug can benefit patients in all markets across the globe. Meanwhile, as the application of platform technology is being expanded to the diagnostics for cardiovascular and cerebrovascular diseases and the treatment of tumor and autoimmune diseases, Inno Medicine is also transcending its R&D pipeline beyond CVD to many other indications.

In an era of unceasing Innovation and technological evolution in the industry, Inno Medicine remains unwavering in its pursuit of progress. Over the years, we have been continuously expanding our R&D team and optimizing the management. We implement rigorous internal control and delicate management, and forge partnership with industry-leading research organizations and prestigious platforms. Championing our corporate value "reverence for life, respect for science, open and inclusive, righteous and diligent", Inno Medicine is committed to making sustained endeavor to march forward and become a global leader in nano-drug targeted delivery technology.

Founder Introduction

Dr. Ma Qian, MD in cardiology, expert physician at Beijing Anzhen Hospital Affiliated to Capital Medical University. Dr. Ma has fifteen years of work experience as a clinical cardiologist with special expertise in atherosclerosis, dyslipidemia, arrhythmia, coronary heart disease, etc. She is a professional member of European Society of Cardiology.

Dr. Ma sits on the expert panel for proposal review for National Natural Science Foundation of China, and is a project lead researcher herself. She also oversees multiple research projects funded by the state and municipality governments. Dr. Ma's outstanding contributions have been recognized through her selection into the Qingmiao Young Scientist Support Program funded by the Beijing municipal government.

Dr. Ma's special research interest lies in the realm of diagnosis and treatment of vulnerable plaque, establishing her as a trailblazer in the domain of targeted therapeutics for atherosclerosis. She possesses 14 invention patents and 5 utility model patents (including 1 granted in the US). Thirteen of her patents are acknowledged globally under the PCT framework.

Founder